Confidence In Factor XIa Inhibition Wavers After Bristol/Janssen And Bayer Data
High Expectations For Next Big Oral Anticoagulant Drug Class
BMS/Janssen’s milvexian and Bayer’s asundexian prevented strokes without major increases in severe bleeding and no fatal bleeds but Phase III outcomes are uncertain based on mixed Phase II data.
